Preface

Tragedies beget attention. Be it airplane crashes that led to stricter safety regulation in the aviation industry or a medical disaster such as Thalidomide that propelled rapid changes in the regulation of the pharmaceutical sector. The same is true for counterfeiting and falsification of medicines. The escalation in the number of fatalities due to counterfeit and falsified medicines has put this issue on the global agenda.

This book highlights the gravity of the situation of prevalence of counterfeit and falsified medicines in the EU. By using specific examples from within the EU, an attempt has been made to cast light on the typical process of counterfeiting and falsification of medicines. The book discusses how the current legal framework in the EU addresses the problem and whether it is adequate.

This book is based on research carried out at Copenhagen Business School between 2014 and 2017, which has been updated and also includes new material on criminal law. I have tried to make it an easy read for an audience belonging to different academic backgrounds.

I would like to acknowledge the indispensable impact of research environments at Copenhagen Business School, Denmark, Max Planck Institute for Innovation and Competition, Munich, Germany, and the Boalt Hall School of Law, Berkeley Law School, University of California, USA.

I would like to express my gratitude to the series editor, Dr Amandine Garde for her constructive suggestions, guidance and patience. I would also like to thank Professor Peter Arnt Nielsen and Professor Andrej Savin for their support and encouragement.

To my late father and mother, my most enthusiastic apostles – thank you. I am deeply grateful to my brother for his constant encouragement and unfailling faith in me. Most of all, I am thankful to my husband and children for their understanding, patience, love and smiles.

Vishv Priya Kohli
Copenhagen, 20 February 2021